AMP Capital Investors Ltd acquired a new position in CytomX Therapeutics Inc (NASDAQ:CTMX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 40,438 shares of the biotechnology company’s stock, valued at approximately $735,000. AMP Capital Investors Ltd owned 0.11% of CytomX Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc raised its position in shares of CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares in the last quarter. Macquarie Group Ltd. bought a new position in CytomX Therapeutics during the 3rd quarter valued at approximately $107,000. Cubist Systematic Strategies LLC bought a new position in CytomX Therapeutics during the 2nd quarter valued at approximately $174,000. Goldman Sachs Group Inc. bought a new position in CytomX Therapeutics during the 1st quarter valued at approximately $190,000. Finally, Voya Investment Management LLC bought a new position in CytomX Therapeutics during the 2nd quarter valued at approximately $203,000. Institutional investors and hedge funds own 63.13% of the company’s stock.
Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) traded up $0.03 during trading on Friday, hitting $25.17. The stock had a trading volume of 330,820 shares, compared to its average volume of 397,401. CytomX Therapeutics Inc has a fifty-two week low of $11.06 and a fifty-two week high of $25.60. The stock has a market capitalization of $966.75 and a P/E ratio of -16.03.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $20.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now directly owns 12,126 shares of the company’s stock, valued at $242,520. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sean A. Mccarthy sold 14,342 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $19.86, for a total value of $284,832.12. Following the sale, the chief executive officer now directly owns 18,587 shares in the company, valued at $369,137.82. The disclosure for this sale can be found here. Insiders sold 70,760 shares of company stock worth $1,533,840 over the last ninety days. Insiders own 4.70% of the company’s stock.
A number of analysts have commented on the company. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Bank of America lifted their target price on CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, BidaskClub downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $32.78.
WARNING: “AMP Capital Investors Ltd Buys New Stake in CytomX Therapeutics Inc (NASDAQ:CTMX)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/amp-capital-investors-ltd-invests-735000-in-cytomx-therapeutics-inc-ctmx-stock.html.
CytomX Therapeutics Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.